09:08 AM EDT, 05/14/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) said Wednesday the first patient has been dosed in a phase 3 trial evaluating daraxonrasib in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer compared to docetaxel chemotherapy.

The trial is expected to enroll around 420 patients, with dual primary endpoints of progression-free survival and overall survival, the company said.

The decision to evaluate daraxonrasib as a monotherapy was informed by early evidence from a single-arm trial showing that the compound had an acceptable safety profile and encouraging antitumor activity, the company said.

Revolution Medicines' ( RVMD ) shares rose by more than 2% in premarket trading.